Background/Aims: Adiponectin is secreted by adipose tissue and circulates in human plasma at high levels. Decreased adiponectin levels are associated with insulin resistance and obesity. The aim of this study was to investigate whether changes in serum adiponectin levels are related to the growth response, insulin levels and insulin resistance during growth hormone (GH) treatment. Methods: The study included 94 short prepubertal children (19 girls and 75 boys). The mean age at the start of daily GH injections was 9.04 ± 2.38 years. Adiponectin levels in serum were measured using an ELISA. Results: At baseline, adiponectin correlated with the first-year growth response (r = 0.26, p = 0.012). Adiponectin decreased significantly after 1 week, 3 months and 1 year from 14.5 ± 5.71 to 13.1 ± 5.22 (p < 0.0001), 10.3 ± 4.82 (p < 0.0001) and 12.5 ± 5.34 μg/ml (p < 0.0001), respectively. There were significant correlations between the first-year growth response and the decrease in adiponectin levels after 3 months and 1 year (r = –0.38, p < 0.0001 and r = –0.47, p < 0.0001, respectively). No correlations between adiponectin, insulin and the homeostasis model assessment of insulin resistance were seen. Conclusions: GH treatment in prepubertal children decreases serum adiponectin levels, and the decrease is correlated to the growth response. No correlations between adiponectin and insulin levels or insulin resistance were found.

Keywords:
Adiponectin, Children, Growth hormone, Insulin-like growth factor-I, Insulin, Growth response
1.
Waters MJ, Hoang HN, Fairlie DP, Pelekanos RA, Brown RJ: New insights into growth hormone action. J Mol Endocrinol 2006;36:1–7.
2.
Wikland KA, Kristrom B, Rosberg S, Svensson B, Nierop AF: Validated multivariate models predicting the growth response to GH treatment in individual short children with a broad range in GH secretion capacities. Pediatr Res 2000;48:475–484.
3.
Wabitsch M, Braun S, Hauner H, Heinze E, Ilondo MM, Shymko R, De Meyts P, Teller WM: Mitogenic and antiadipogenic properties of human growth hormone in differentiating human adipocyte precursor cells in primary culture. Pediatr Res 1996;40:450–456.
4.
Brook CG: Effect of human growth hormone treatment on adipose tissue in children. Arch Dis Child 1973;48:725–728.
5.
Phillip M, Moran O, Lazar L: Growth without growth hormone. J Pediatr Endocrinol Metab 2002;15(suppl 5):1267–1272.
6.
Berg AH, Combs TP, Scherer PE: ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 2002;13:84–89.
7.
Trayhurn P: Endocrine and signalling role of adipose tissue: new perspectives on fat. Acta Physiol Scand 2005;184:285–293.
8.
Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, Shen J, Vinson C, Rueger JM, Karsenty G: Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 2000;100:197–207.
9.
Oshima K, Nampei A, Matsuda M, Iwaki M, Fukuhara A, Hashimoto J, Yoshikawa H, Shimomura I: Adiponectin increases bone mass by suppressing osteoclast and activating osteoblast. Biochem Biophys Res Commun 2005;331:520–526.
10.
Havel PJ: Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin. Curr Opin Lipidol 2002;13:51–59.
11.
Tsao TS, Lodish HF, Fruebis J: ACRP30, a new hormone controlling fat and glucose metabolism. Eur J Pharmacol 2002;440:213–221.
12.
Wolf G: Adiponectin: a regulator of energy homeostasis. Nutr Rev 2003;61:290–292.
13.
Pajvani UB, Du X, Combs TP, Berg AH, Rajala MW, Schulthess T, Engel J, Brownlee M, Scherer PE: Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity. J Biol Chem 2003;278:9073–9085.
14.
Wang Y, Lam KS, Xu JY, Lu G, Xu LY, Cooper GJ, Xu A: Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization-dependent manner. J Biol Chem 2005;280:18341–18347.
15.
Wong GW, Wang J, Hug C, Tsao TS, Lodish HF: A family of Acrp30/adiponectin structural and functional paralogs. Proc Natl Acad Sci USA 2004;101:10302–10307.
16.
Karlberg J: On the construction of the infancy-childhood-puberty growth standard. Acta Paediatr Scand Suppl 1989;356:26–37.
17.
Kristrom B, Karlberg J, Albertsson-Wikland K: Prediction of the growth response of short prepubertal children treated with growth hormone. Swedish Paediatric Study Group for GH treatment. Acta Paediatr 1995;84:51–57.
18.
Albertsson-Wikland K, Jansson C, Rosberg S, Novamo A: Time-resolved immunofluorometric assay of human growth hormone. Clin Chem 1993;39:1620–1625.
19.
Boguszewski M, Rosberg S, Albertsson-Wikland K: Spontaneous 24-hour growth hormone profiles in prepubertal small for gestational age children. J Clin Endocrinol Metab 1995;80:2599–2606.
20.
Kristrom B, Jansson C, Rosberg S, Albertsson-Wikland K: Growth response to growth hormone (GH) treatment relates to serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in short children with various GH secretion capacities. Swedish Study Group for Growth Hormone Treatment. J Clin Endocrinol Metab 1997;82:2889–2898.
21.
Tanner JM, Whitehouse RH, Cameron N, Marshall WA, Healy MJR, Goldstein H: Assessment of Skeletal Maturity and Prediction of Adult Height (TW2 Method). London, Academic Press, 1983.
22.
Blum WF, Breier BH: Radioimmunoassays for IGFs and IGFBPs. Growth Regul 1994;4(suppl 1):11–19.
23.
Carlsson B, Ankarberg C, Rosberg S, Norjavaara E, Albertsson-Wikland K, Carlsson LM: Serum leptin concentrations in relation to pubertal development. Arch Dis Child 1997;77:396–400.
24.
Martos-Moreno GA, Barrios V, Argente J: Normative data for adiponectin, resistin, interleukin 6, and leptin/receptor ratio in a healthy Spanish pediatric population: relationship with sex steroids. Eur J Endocrinol 2006;155:429–434.
25.
Lihn AS, Pedersen SB, Richelsen B: Adiponectin: action, regulation and association to insulin sensitivity. Obes Rev 2005;6:13–21.
26.
Eden Engstrom B, Burman P, Holdstock C, Karlsson FA: Effects of growth hormone (GH) on ghrelin, leptin, and adiponectin in GH-deficient patients. J Clin Endocrinol Metab 2003;88:5193–5198.
27.
Fors H, Matsuoka H, Bosaeus I, Rosberg S, Wikland KA, Bjarnason R: Serum leptin levels correlate with growth hormone secretion and body fat in children. J Clin Endocrinol Metab 1999;84:3586–3590.
28.
Cianfarani S, Martinez C, Maiorana A, Scire G, Spadoni GL, Boemi S: Adiponectin levels are reduced in children born small for gestational age and are inversely related to postnatal catch-up growth. J Clin Endocrinol Metab 2004;89:1346–1351.
29.
Ibanez L, Fucci A, Valls C, Ong K, Dunger D, de Zegher F: Neutrophil count in small-for-gestational age children: contrasting effects of metformin and growth hormone therapy. J Clin Endocrinol Metab 2005;90:3435–3439.
30.
Ong K, Beardsall K, de Zegher F: Growth hormone therapy in short children born small for gestational age. Early Hum Dev 2005;81:973–980.
31.
Ciresi A, Amato MC, Criscimanna A, Mattina A, Vetro C, Galluzzo A, D’Acquisto G, Giordano C: Metabolic parameters and adipokine profile during GH replacement therapy in children with GH deficiency. Eur J Endocrinol 2007;156:353–360.
32.
Diez JJ, Iglesias P: The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 2003;148:293–300.
33.
Dahlgren J, Kristrom B, Niklasson A, Nierop AF, Rosberg S, Albertsson-Wikland K: Models predicting the growth response to growth hormone treatment in short children independent of GH status, birth size and gestational age. BMC Med Inform Decis Mak 2007;7:40.
34.
Ranke MB: New paradigms for growth hormone treatment in the 21st century: prediction models. J Pediatr Endocrinol Metab 2000;13(suppl 6):1365–1369.
35.
Fasshauer M, Klein J, Kralisch S, Klier M, Lossner U, Bluher M, Paschke R: Growth hormone is a positive regulator of adiponectin receptor 2 in 3T3-L1 adipocytes. FEBS Lett 2004;558:27–32.
36.
Shinoda Y, Yamaguchi M, Ogata N, Akune T, Kubota N, Yamauchi T, Terauchi Y, Kadowaki T, Takeuchi Y, Fukumoto S, Ikeda T, Hoshi K, Chung UI, Nakamura K, Kawaguchi H: Regulation of bone formation by adiponectin through autocrine/paracrine and endocrine pathways. J Cell Biochem 2006;99:196–208.
37.
Berner HS, Lyngstadaas SP, Spahr A, Monjo M, Thommesen L, Drevon CA, Syversen U, Reseland JE: Adiponectin and its receptors are expressed in bone-forming cells. Bone 2004;35:842–849.
38.
Luo XH, Guo LJ, Yuan LQ, Xie H, Zhou HD, Wu XP, Liao EY: Adiponectin stimulates human osteoblasts proliferation and differentiation via the MAPK signaling pathway. Exp Cell Res 2005;309:99–109.
39.
Lanes R, Soros A, Gunczler P, Paoli M, Carrillo E, Villaroel O, Palacios A: Growth hormone deficiency, low levels of adiponectin, and unfavorable plasma lipid and lipoproteins. J Pediatr 2006;149:324–329.
40.
Berryman DE, List EO, Coschigano KT, Behar K, Kim JK, Kopchick JJ: Comparing adiposity profiles in three mouse models with altered GH signaling. Growth Horm IGF Res 2004;14:309–318.
41.
Willemsen RH, van Dijk M, de Rijke YB, van Toorenenbergen AW, Mulder PG, Hokken-Koelega AC: Effect of growth hormone therapy on serum adiponectin and resistin levels in short, small-for-gestational-age children and associations with cardiovascular risk parameters. J Clin Endocrinol Metab 2007;92:117–123.
42.
Nam SY, Marcus C: Growth hormone and adipocyte function in obesity. Horm Res 2000;53(suppl 1):87–97.
43.
Harrell JS, Jessup A, Greene N: Changing our future: obesity and the metabolic syndrome in children and adolescents. J Cardiovasc Nurs 2006;21:322–330.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.